

Title (en)
ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

Title (de)
ANTI-NTB-A-ANTIKÖRPER SOWIE ZUGEHÖRIGE ZUSAMMENSETZUNGEN UND VERFAHREN

Title (fr)
ANTICORPS ANTI-NTB-A AINSI QUE COMPOSITIONS ET PROCÉDÉS ASSOCIÉS

Publication
EP 3316909 B1 20230830 (EN)

Application
EP 16818762 A 20160630

Priority
• US 201562186596 P 20150630
• US 201662321849 P 20160413
• US 2016040307 W 20160630

Abstract (en)
[origin: WO2017004330A1] Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.

IPC 8 full level
A61K 39/395 (2006.01); **A61K 47/68** (2017.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: CN EP IL KR US)
A61K 47/65 (2017.08 - CN IL US); **A61K 47/6803** (2017.08 - CN EP IL US); **A61K 47/6811** (2017.08 - CN EP IL KR US);
A61K 47/6851 (2017.08 - CN EP IL KR US); **A61P 35/00** (2018.01 - CN EP IL US); **C07K 16/2803** (2013.01 - CN EP IL KR US);
A61K 2039/505 (2013.01 - EP IL KR US); **A61K 2039/572** (2013.01 - CN IL US); **A61K 2121/00** (2013.01 - IL US);
C07K 2317/24 (2013.01 - CN EP IL KR US); **C07K 2317/33** (2013.01 - CN EP IL US); **C07K 2317/567** (2013.01 - CN EP IL KR US);
C07K 2317/73 (2013.01 - CN EP IL KR US); **C07K 2317/732** (2013.01 - CN EP IL KR US); **C07K 2317/92** (2013.01 - CN EP IL KR US)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2017004330 A1 20170105; AU 2016287647 A1 20171207; AU 2022209203 A1 20220915; BR 112017027498 A2 20180911;
CA 2986796 A1 20170105; CN 107735105 A 20180223; CN 107735105 B 20220916; CN 116063502 A 20230505; DK 3316909 T3 20231113;
EA 201890158 A1 20180629; EP 3316909 A1 20180509; EP 3316909 A4 20190109; EP 3316909 B1 20230830; EP 4302784 A2 20240110;
EP 4302784 A3 20240313; ES 2955961 T3 20231211; FI 3316909 T3 20230907; HK 1253306 A1 20190614; HU E063320 T2 20240128;
IL 256295 A 20180228; IL 256295 B1 20230701; IL 256295 B2 20231101; IL 303690 A 20230801; JP 2018520671 A 20180802;
JP 2021087427 A 20210610; JP 6879947 B2 20210602; JP 7194762 B2 20221222; KR 20180021705 A 20180305; MX 2017017049 A 20180306;
PL 3316909 T3 20231120; PT 3316909 T 20231122; SG 10202005460R A 20200729; SI 3316909 T1 20231030; US 11351269 B2 20220607;
US 2018169257 A1 20180621; US 2023218776 A1 20230713; ZA 201707869 B 20231025

DOCDB simple family (application)
US 2016040307 W 20160630; AU 2016287647 A 20160630; AU 2022209203 A 20220725; BR 112017027498 A 20160630;
CA 2986796 A 20160630; CN 201680038295 A 20160630; CN 202211047388 A 20160630; DK 16818762 T 20160630;
EA 201890158 A 20160630; EP 16818762 A 20160630; EP 23190081 A 20160630; ES 16818762 T 20160630; FI 16818762 T 20160630;
HK 18112598 A 20181002; HU E16818762 A 20160630; IL 25629517 A 20171213; IL 30369023 A 20230613; JP 2017567180 A 20160630;
JP 2021010171 A 20210126; KR 20177036145 A 20160630; MX 2017017049 A 20160630; PL 16818762 T 20160630; PT 16818762 T 20160630;
SG 10202005460R A 20160630; SI 201631741 T 20160630; US 201615739363 A 20160630; US 202218058454 A 20221123;
ZA 201707869 A 20171120